S100A2, S100 calcium binding protein A2, 6273

N. diseases: 72; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.100 AlteredExpression phenotype BEFREE Interestingly, whereas none of the metastases expressed S100A2 mRNA, and the expression level was low in 6 cell lines established from primary melanomas, all nevi showed moderate to high expression levels. 9291441 1997
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE Since transcription of a number of known tumor suppressor genes is also repressed by methylation, our observation is consistent with the suggestion that S100A2 might have a tumor suppressor function. 9481475 1997
CUI: C0025202
Disease: melanoma
melanoma 		0.020 AlteredExpression disease BEFREE The observed differences in expression patterns of the 3 S100 genes suggest distinct roles of their products in melanoma tumorigenesis and/or metastasis, and the results encourage studies to evaluate the potential value of using S100A2 and S100A6 expression levels as markers in the clinical management of melanoma. 9291441 1997
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. 9481475 1997
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.020 AlteredExpression group BEFREE Interestingly, whereas none of the metastases expressed S100A2 mRNA, and the expression level was low in 6 cell lines established from primary melanomas, all nevi showed moderate to high expression levels. 9291441 1997
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.010 Biomarker disease BEFREE Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. 9481475 1997
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 AlteredExpression disease BEFREE S100A2 protein has previously been shown to be expressed in normal human breast epithelium, but not in human breast carcinoma cell lines. 11076656 2000
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.010 Biomarker group BEFREE A suppression subtraction cDNA library representing mRNAs expressed at a higher level in a benign breast tumour-derived cell line relative to the malignant MCF-7A cell line contained cDNAs corresponding to mRNAs for plasminogen activator inhibitor I, annexin VIII and the EF-hand protein S100A2. 11076656 2000
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma 		0.100 Biomarker group BEFREE Positive immunohistochemical staining of S100A2 was detected in the majority (75-83%) of normal and hyperplastic lung tissues, whereas it was detected in <10% of metaplastic lung tissues, squamous cell carcinoma, and adenocarcinoma. 11691825 2001
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.100 AlteredExpression disease BEFREE Furthermore, S100A2 mRNA and protein were undetectable in 8 and expressed at a reduced level in 3 of 11 non-small cell lung cancer (NSCLC) cell lines. 11691825 2001
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. 11304580 2001
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. 11691825 2001
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.090 Biomarker disease BEFREE S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. 11304580 2001
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.050 Biomarker disease BEFREE Our results suggest that S100A2 expression is suppressed early during lung carcinogenesis, possibly by hypermethylation of its promoter, and that its loss may be a contributing factor in lung cancer development or a biomarker of early changes in this process. 11691825 2001
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.050 Biomarker phenotype BEFREE Our results suggest that S100A2 expression is suppressed early during lung carcinogenesis, possibly by hypermethylation of its promoter, and that its loss may be a contributing factor in lung cancer development or a biomarker of early changes in this process. 11691825 2001
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.050 Biomarker disease BEFREE Our results suggest that S100A2 expression is suppressed early during lung carcinogenesis, possibly by hypermethylation of its promoter, and that its loss may be a contributing factor in lung cancer development or a biomarker of early changes in this process. 11691825 2001
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.050 Biomarker disease BEFREE Our results suggest that S100A2 expression is suppressed early during lung carcinogenesis, possibly by hypermethylation of its promoter, and that its loss may be a contributing factor in lung cancer development or a biomarker of early changes in this process. 11691825 2001
CUI: C1168401
Disease: Squamous cell carcinoma of the head and neck
Squamous cell carcinoma of the head and neck 		0.020 AlteredExpression disease BEFREE To this end, we made use of five in vitro human head and neck squamous cell carcinoma lines in which we characterized S100A2 expression at both RNA and protein level. 11304580 2001
CUI: C0033860
Disease: Psoriasis
Psoriasis 		0.010 Biomarker disease BEFREE Our data explain conflicting results in the literature regarding the sequence of S100A2 but provide no support for a direct causal role for S100A2 in psoriasis. 11260185 2001
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.100 AlteredExpression disease BEFREE Whilst it has been reported that S100A2 is downregulated in NSCLC at an early stage, our microarray, cmRT-PCR, Western and immunohistochemistry data indicate that it is strongly expressed in the majority of tumours. 12400018 2002
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Quantitative real-time PCR on primary GC samples demonstrated overexpression of S100A2 in 18 of 20 tumors (90%). 12460893 2002
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.090 AlteredExpression disease LHGDN Expression and prognostic significance of S100A2 protein in squamous cell carcinoma of the esophagus. 11956617 2002
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.040 Biomarker group BEFREE This decrease in S100A2 staining from normal to cancer cases is more pronounced in glandular than in squamous epithelial tissue. 11813862 2002
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.040 Biomarker group BEFREE This decrease in S100A2 staining from normal to cancer cases is more pronounced in glandular than in squamous epithelial tissue. 11813862 2002
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.030 AlteredExpression disease BEFREE Quantitative real-time PCR on primary GC samples demonstrated overexpression of S100A2 in 18 of 20 tumors (90%). 12460893 2002